Dr. K Bae, MD

NPI: 1821014143
Total Payments
$307,735
2023 Payments
$93.17
Companies
7
Transactions
25

Payment Breakdown by Category

Consulting$236,667 (76.9%)
Royalty/License$70,900 (23.0%)
Food & Beverage$168.17 (0.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $236,667 18 76.9%
Royalty or License $70,900 4 23.0%
Food and Beverage $168.17 3 0.1%

Top Paying Companies

Company Total Records Latest Year
Kadmon Corporation LLC $174,250 10 $0 (2021)
Liebel-Flarsheim LLC $70,900 4 $0 (2020)
SANOFI-AVENTIS U.S. LLC $43,648 2 $0 (2022)
Otsuka Pharmaceutical Development & Commercialization, Inc. $11,055 5 $0 (2020)
GENZYME CORPORATION $4,251 1 $0 (2020)
Otsuka America Pharmaceutical, Inc. $3,538 2 $0 (2020)
AstraZeneca Pharmaceuticals LP $93.17 1 $0 (2023)

Payment History by Year

Year Amount Transactions Top Company
2023 $93.17 1 AstraZeneca Pharmaceuticals LP ($93.17)
2022 $20,000 1 SANOFI-AVENTIS U.S. LLC ($20,000)
2021 $40,000 1 Kadmon Corporation LLC ($40,000)
2020 $75,625 8 Kadmon Corporation LLC ($40,000)
2019 $96,617 9 Kadmon Corporation LLC ($41,750)
2018 $33,400 3 Liebel-Flarsheim LLC ($22,900)
2017 $42,000 2 Kadmon Corporation LLC ($42,000)

All Payment Transactions

25 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
08/10/2023 AstraZeneca Pharmaceuticals LP Food and Beverage In-kind items and services $93.17 General
03/16/2022 SANOFI-AVENTIS U.S. LLC Consulting Fee Cash or cash equivalent $20,000.00 General
07/22/2021 Kadmon Corporation LLC Consulting Fee Cash or cash equivalent $40,000.00 General
10/07/2020 Kadmon Corporation LLC Consulting Fee Cash or cash equivalent $20,000.00 General
08/27/2020 GENZYME CORPORATION Consulting Fee Cash or cash equivalent $4,251.00 General
08/24/2020 Liebel-Flarsheim LLC OptiVantage (Device) Royalty or License Cash or cash equivalent $17,600.00 General
Category: Medical Imaging
08/24/2020 Liebel-Flarsheim LLC OptiOne (Device) Royalty or License Cash or cash equivalent $5,600.00 General
Category: Medical Imaging
07/01/2020 Otsuka Pharmaceutical Development & Commercialization, Inc. Consulting Fee Cash or cash equivalent $4,636.00 General
06/03/2020 Otsuka America Pharmaceutical, Inc. JYNARQUE (Drug) Consulting Fee Cash or cash equivalent $1,586.00 General
Category: NEPHROLOGY
04/16/2020 Otsuka America Pharmaceutical, Inc. JYNARQUE (Drug) Consulting Fee Cash or cash equivalent $1,952.00 General
Category: NEPHROLOGY
02/11/2020 Kadmon Corporation LLC Consulting Fee Cash or cash equivalent $20,000.00 General
12/09/2019 Otsuka Pharmaceutical Development & Commercialization, Inc. JYNARQUE (Drug) Consulting Fee Cash or cash equivalent $1,464.00 General
Category: NEPHROLOGY
11/25/2019 Liebel-Flarsheim LLC OptiVantage (Device) Royalty or License Cash or cash equivalent $24,800.00 General
Category: Medical Imaging
11/10/2019 Otsuka Pharmaceutical Development & Commercialization, Inc. JYNARQUE (Drug) Food and Beverage In-kind items and services $50.00 General
Category: NEPHROLOGY
11/10/2019 Otsuka Pharmaceutical Development & Commercialization, Inc. JYNARQUE (Drug) Food and Beverage In-kind items and services $25.00 General
Category: NEPHROLOGY
08/27/2019 Kadmon Corporation LLC Consulting Fee Cash or cash equivalent $20,000.00 General
05/13/2019 Otsuka Pharmaceutical Development & Commercialization, Inc. Consulting Fee Cash or cash equivalent $4,880.00 General
03/19/2019 Kadmon Corporation LLC Consulting Fee Cash or cash equivalent $20,000.00 General
03/19/2019 Kadmon Corporation LLC Consulting Fee Cash or cash equivalent $1,750.00 General
02/15/2019 SANOFI-AVENTIS U.S. LLC NO PRODUCT DISCUSSED (Drug) Consulting Fee Cash or cash equivalent $23,648.00 General
11/06/2018 Liebel-Flarsheim LLC OptiVantage (Device) Royalty or License Cash or cash equivalent $22,900.00 General
Category: Medical Imaging
08/22/2018 Kadmon Corporation LLC Consulting Fee Cash or cash equivalent $3,500.00 General
04/17/2018 Kadmon Corporation LLC Consulting Fee Cash or cash equivalent $7,000.00 General
11/28/2017 Kadmon Corporation LLC Consulting Fee Cash or cash equivalent $12,000.00 General
05/23/2017 Kadmon Corporation LLC Consulting Fee Cash or cash equivalent $30,000.00 General

About Dr. K Bae, MD

Dr. K Bae, MD is a Diagnostic Radiology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821014143.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. K Bae, MD has received a total of $307,735 in payments from pharmaceutical and medical device companies, with $93.17 received in 2023. These payments were reported across 25 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($236,667).

Practice Information

  • Specialty Diagnostic Radiology
  • Location Saint Louis, MO
  • Active Since 07/14/2006
  • Last Updated 08/18/2011
  • Taxonomy Code 2085R0202X
  • Entity Type Individual
  • NPI Number 1821014143

Products in Payments

  • OptiVantage (Device) $65,300
  • NO PRODUCT DISCUSSED (Drug) $23,648
  • OptiOne (Device) $5,600
  • JYNARQUE (Drug) $5,077

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Diagnostic Radiology Doctors in Saint Louis